← Product Code FRO · K071056 # NEUTROPHASE WOUND CLEANSER (K071056) _Novabay Pharmaceuticals · FRO · Sep 28, 2007 · SU · SESE_ **Canonical URL:** https://fda.innolitics.com/device/K071056 ## Device Facts - **Applicant:** Novabay Pharmaceuticals - **Product Code:** FRO - **Decision Date:** Sep 28, 2007 - **Decision:** SESE - **Submission Type:** Traditional - **Device Class:** Class U - **Review Panel:** SU - **Attributes:** Therapeutic ## Intended Use The device is intended for moistening absorbent wound dressings and irrigating and cleaning minor cuts, minor burns, superficial abrasions and minor irritations of the skin. It is also intended for moistening, debriding and irrigating acute and chronic dermal lesions, such as Stage I-IV pressure ulcers, stasis ulcers, leg ulcers, diabetic foot ulcers, post surgical wounds, first and second degree burns, abrasions and minor irritations of the skin. ## Device Story NeutroPhase is a liquid wound cleansing solution. Mechanism of action relies on mechanical irrigation; fluid movement across wound surface facilitates removal of foreign objects, dirt, and debris. Used in clinical or home settings for wound management. Healthcare providers or patients apply the solution to moisten dressings or irrigate wounds. Output is a clean, moistened wound environment, aiding in debridement and healing of acute and chronic lesions. ## Clinical Evidence Bench testing only. Verification testing confirmed device conformance with functional specifications. ## Technological Characteristics Liquid wound cleansing solution. Mechanical irrigation principle. No electronic components, software, or specific material standards cited. ## Predicate Devices - Dermacyn Wound Care ([K060113](/device/K060113.md)) - Dermacyn Wound Irrigation ([K042729](/device/K042729.md)) ## Submission Summary (Full Text) > This content was OCRed from public FDA records by [Innolitics](https://innolitics.com). If you use, quote, summarize, crawl, or train on this content, cite Innolitics at https://innolitics.com. > > Innolitics is a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices, including [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/). {0}------------------------------------------------ K071056 ge 1/2 NovaBay Pharmaceuticals, Inc Response to Request for Additional Information SEP 2 8 2007 Revision to 510(k) summary - pages 028-029 ## 510(k) Summary Prepared April 11, 2007 (Revised September 19, 2007) | Submitted by: | NovaBay Pharmaceuticals
5980 Horton Street
Suite 550
Emeryville, California 94608 | |-----------------|------------------------------------------------------------------------------------------------------------------| | Contact Person: | Behzad Khosrovi Ph.D.
Telephone: (510) 899 8852
Fax: (510) 740 3986
e-mail: bkhosrovi@novabaypharma.com | | Product Name: | NeutroPhase™ | | Common Name: | Liquid bandage/wound cleanser | | Classification: | KMF 880.5090 Class II | Predicate Devices: | Device Name | Manufacturer | K Number | |------------------------------|--------------------------------------|----------| | Dermacyn Wound
Care | Oculus Innovative
Sciences, Inc | K060113 | | Dermacyn Wound
Irrigation | Oculus Innovative
Sciences, Inc.. | K042729 | # Description of Device: NeutroPhase™ is a wound cleansing solution for irrigating and cleansing of dermal wounds. The mechanical action of fluid moving across the wound provides the mechanism of action and aids in the removal of foreign objects such as dirt and debris. {1}------------------------------------------------ K071056 page 2/2 NovaBay Pharmaceuticals, Inc Response to Request for Additional Information ## Intended Use: The device is intended for moistening absorbent wound dressings and irrigating and cleaning minor cuts, minor burns, superficial abrasions and minor irritations of the skin, It is also intended for moistening, debriding and irrigating acute and chronic dermal lesions, such as Stage I-IV pressure ulcers, stasis ulcers, leg ulcers, diabetic foot ulcers, post surgical wounds, first and second degree burns, abrasions and minor irritations of the skin. #### Comparison with Predicate Devices: The submission device and the predicate devices have substantially equivalent intended use and technological specifications. #### Performance: The NeutroPhase™ verification testing has confirmed the device's conformance with specifications. The functional specifications do not include any significant differences from those of the predicates. {2}------------------------------------------------ Image /page/2/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a circular seal with the text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" arranged around the perimeter. Inside the circle is a stylized image of an eagle with three lines representing its wings and body. Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850 SEP 2 8 2007 NovaBay Pharmaceuticals, Inc. % Behzad Khosrovi Ph.D. Vice President of Research and Development 5980 Horton Street. Ste. 550 Emeryville, California 94608 Re: K071056 Trade/Device Name: NeutroPhase "Wound Cleanser Regulation Number: 21 CFR 880.5090 Regulation Name: Liquid bandage Regulatory Class: I Product Code: KMF Dated: September 18, 2007 Received: September 20, 2007 Dear Mr. Khosrovi: We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050. {3}------------------------------------------------ Page 2 - Mr. Khosrovi This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market. If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (240) 276-0115. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (240) 276-3150 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html. Sincerely yours. Mark N. Melkerson Director Division of General, Restorative and Neurological Devices Office of Device Evaluation Center for Devices and Radiological Health Enclosure {4}------------------------------------------------ NovaBay Pharmaceuticals, Inc Response to Request for Additional Information ### Revision to FDA Indications for use form- pages 012 510(k) Number (if known): Device Name: NeutroPhase™ Wound Cleanser Indications For Use: The device is intended for moistening absorbent wound dressings and irrigating and cleaning minor cuts, minor burns, superficial abrasions and minor irritations of the skin. It is also intended for moistening, debriding and irrigating acute and chronic dermal lesions, such as Stage I-IV pressure ulcers, stasis ulcers, leg ulcers, diabetic foot ulcers, post surgical wounds, first and second degree burns, abrasions and minor irritations of the skin. (**Division Sign Off**) Division of General, Restorative, and Neurological Devices 510(k) Number_________________________________________________________________________________________________________________________________________________________________ Prescription Use X (Per 21CFR 801) (PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED) Concurrence Of CDRH, Office Of Device Evaluation (ODE) --- **Source:** [https://fda.innolitics.com/device/K071056](https://fda.innolitics.com/device/K071056) **Published by [Innolitics](https://innolitics.com)** — a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices. If you're preparing [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/), [get in touch](https://innolitics.com/contact). **Cite:** Innolitics at https://innolitics.com